CD34 and neoplasm: Of 223 HIS mice engrafted with human CD34+ hematopoietic stem and progenitor cells (HSPCs) from 27 different donors and implanted with HT-29 tumors, 76 (34%) rejected the tumors, 40 (18%) showed tumor regression, and 107 (48%) showed tumor progression (Fig. 1A).